2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
|Articles|September 5, 2014
PDA Initiates Quality Culture Survey
Author(s)Pharmaceutical Technology Editors
PDA surveys are designed to evaluate quality metrics practices at member organizations.
Advertisement
The Parenteral Drug Association (PDA) launched on Sept. 5 the first of two surveys on quality culture metrics as part the organization’s continuing program to evaluate quality metrics that can inform the regulator’s risk-based inspection programs.
A link to first survey has been sent to selected PDA members with a background or interest in pharmaceutical quality. On Sept. 6, a second survey was launched with controlled participation limited to three or four executives at selected companies. The surveys will be open for participation until Oct. 2, 2014.
PDA reports that it is conducting the 2014 PDA Quality Culture Metrics Survey to understand to what degree PDA members’ companies are measuring quality culture and to identify attributes of quality culture appropriate for use as metrics. Respondents are encouraged to base their answers on tools and approaches used at their local work site or facility, the organization reports.
Results will be presented at the 2014 PDA Pharmaceutical Quality Metrics Conference on Dec. 4, 2014 in Washington, DC.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Advertisement
Advertisement